---
title: "Hanbon Technology (688755): Won the procurement project of North China Pharmaceutical Huasheng Co., Ltd., with a bid amount of 1.498 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286893239.md"
description: "Hanbon Technology (688755) won the bid for a procurement project from North China Pharmaceutical Huasheng Co., Ltd., with an amount of 1.498 million yuan. The operating income for 2024 is expected to be 689 million yuan, with a growth rate of 11.61%; the net profit is expected to be 79 million yuan, with a growth rate of 54.06%. In the first half of 2025, the operating income is expected to be 349 million yuan, with a growth rate of 5.99%; the net profit is expected to be 28 million yuan, a decrease of 26.24%"
datetime: "2026-05-19T10:16:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286893239.md)
  - [en](https://longbridge.com/en/news/286893239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286893239.md)
---

# Hanbon Technology (688755): Won the procurement project of North China Pharmaceutical Huasheng Co., Ltd., with a bid amount of 1.498 million yuan

According to Tongbi Finance, data from Qichacha shows that Jiangsu Hanbon Technology Co., Ltd. announced on May 19, 2026, that it won the bid for the procurement project of North China Pharmaceutical Huasheng Co., Ltd., with a bid amount of 1.498 million yuan, based on the "Transaction Announcement for High-Pressure Chromatography Column System of North China Pharmaceutical Huasheng Co., Ltd."

Related listed company: Hanbon Technology (688755.SH)

_Tongbi Finance Tip:_

_Hanbon Technology (688755.SH) reported an operating income of 691 million yuan in 2024, with a growth rate of 11.61%. The net profit attributable to the parent company was 79 million yuan, with a growth rate of 54.06%, and the return on net assets was 11.51%._

_In the first half of 2025, the company's operating income was 349 million yuan, with a growth rate of 5.99%. The net profit attributable to the parent company was 28 million yuan, with a growth rate of -26.24%._

_The company currently belongs to the industrial sector, with the main product types being specialized equipment and components. The 2024 report shows the main composition of its business: production-grade small molecule drug separation and purification equipment: 61.26%; production-grade large molecule drug separation and purification equipment: 25.9%; laboratory small molecule drug separation and purification equipment: 5.41%; others: 5.29%; laboratory large molecule drug separation and purification equipment: 2.09%; other businesses: 0.05%._

### Related Stocks

- [688755.CN](https://longbridge.com/en/quote/688755.CN.md)
- [600812.CN](https://longbridge.com/en/quote/600812.CN.md)

## Related News & Research

- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)